MENU
+Compare
HLUBF
Stock ticker: OTC
AS OF
Oct 8 closing price
Price
$5.59
Change
+$0.12 (+2.19%)
Capitalization
6.87B

HLUBF H. Lundbeck A/S Forecast, Technical & Fundamental Analysis

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products... Show more

HLUBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for HLUBF with price predictions
Oct 17, 2025

Aroon Indicator for HLUBF shows an upward move is likely

HLUBF's Aroon Indicator triggered a bullish signal on October 17, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 48 similar instances where the Aroon Indicator showed a similar pattern. In of the 48 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 01, 2025. You may want to consider a long position or call options on HLUBF as a result. In of 23 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for HLUBF turned negative on September 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.471) is normal, around the industry mean (17.685). P/E Ratio (10.194) is within average values for comparable stocks, (72.923). HLUBF's Projected Growth (PEG Ratio) (5.973) is slightly higher than the industry average of (2.078). Dividend Yield (0.025) settles around the average of (0.030) among similar stocks. P/S Ratio (1.513) is also within normal values, averaging (46.506).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HLUBF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLUBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
HLUBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Ottiliavej 9
Phone
+45 36301311
Employees
5681
Web
https://www.lundbeck.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ZECP33.710.23
+0.69%
Zacks Earnings Consistent ETF
RSMR21.440.09
+0.40%
FT Vest U.S. Equity Equal Weight Buffer ETF - March
IGRO80.530.20
+0.25%
iShares International Dividend Gr ETF
HDGE16.69-0.02
-0.12%
AdvisorShares Ranger Equity Bear ETF
GENT10.43-0.02
-0.19%
Genter Capital Taxable Qual Interm ETF

HLUBF and Stocks

Correlation & Price change

A.I.dvisor tells us that HLUBF and HLBBF have been poorly correlated (+18% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLUBF and HLBBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLUBF
1D Price
Change %
HLUBF100%
N/A
HLBBF - HLUBF
18%
Poorly correlated
N/A
HLNCF - HLUBF
7%
Poorly correlated
+2.50%
ESAIY - HLUBF
5%
Poorly correlated
+1.75%
AKAN - HLUBF
2%
Poorly correlated
+2.69%
HLN - HLUBF
1%
Poorly correlated
+3.04%
More

Groups containing HLUBF

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLUBF
1D Price
Change %
HLUBF100%
N/A
Pharmaceuticals
category (383 stocks)
-2%
Poorly correlated
-0.25%
Pharmaceuticals: Generic
category (219 stocks)
-4%
Poorly correlated
-0.27%